| Title |
Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application
|
|---|---|
| Published in |
International Journal of Clinical Oncology, March 2016
|
| DOI | 10.1007/s10147-016-0968-y |
| Pubmed ID | |
| Authors |
Masaki Mandai, Junzo Hamanishi, Kaoru Abiko, Noriomi Matsumura, Tsukasa Baba, Ikuo Konishi |
| Abstract |
Tumor immune therapy, especially anti-programmed cell death ligand-1/programmed cell death-1 (PD-L1/PD-1) treatment, is currently the focus of substantial attention. Ovarian cancer is the leading cause of mortality from gynecological malignancies, and novel treatment modalities, including immune therapy, are needed. However, a basic understanding of tumor immunity associated with the PD-L1/PD-1 signal has only recently emerged. In this review, we first discuss the importance of local tumor immunity, which affects the clinical outcome of ovarian cancer. We subsequently provide an overview of the basic findings regarding how the PD-L1/PD-1 signal influences local tumor immunity in ovarian cancer. Finally, we discuss what is needed to apply immune therapy in future clinical medicine. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Korea, Republic of | 1 | 2% |
| Unknown | 45 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 21% |
| Student > Ph. D. Student | 7 | 15% |
| Student > Bachelor | 5 | 11% |
| Student > Master | 5 | 11% |
| Student > Postgraduate | 4 | 9% |
| Other | 9 | 19% |
| Unknown | 7 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 40% |
| Biochemistry, Genetics and Molecular Biology | 7 | 15% |
| Agricultural and Biological Sciences | 5 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 9% |
| Immunology and Microbiology | 4 | 9% |
| Other | 1 | 2% |
| Unknown | 7 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 March 2016.
All research outputs
#20,315,221
of 22,856,968 outputs
Outputs from International Journal of Clinical Oncology
#613
of 914 outputs
Outputs of similar age
#252,964
of 299,532 outputs
Outputs of similar age from International Journal of Clinical Oncology
#7
of 9 outputs
Altmetric has tracked 22,856,968 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 914 research outputs from this source. They receive a mean Attention Score of 3.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 299,532 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.